ADC	Antibody–Drug Conjugate
ALK	Anaplastic Lymphoma Kinase
ATC	Anaplastic Thyroid Carcinoma
BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase
CDx	Companion Diagnostic
CI	Confidence Interval
CNS	Central Nervous System
CRC	Colorectal Cancer
CR	Complete Response
ctDNA	Circulating Tumor DNA
DoR	Duration of Response
EGFR	Epidermal Growth Factor Receptor
FDA	U.S. Food and Drug Administration
FGFR	Fibroblast Growth Factor Receptor
GTP/GDP	Guanosine Triphosphate/Guanosine Diphosphate
HER2	Human Epidermal Growth Factor Receptor 2
HER3	Human Epidermal Growth Factor Receptor 3
HNSCC	Head and Neck Squamous Cell Carcinoma
HRR	Homologous Recombination Repair
H&N	Head and Neck
IHC	Immunohistochemistry
ILD	Interstitial Lung Disease
MAPK	Mitogen-Activated Protein Kinase
MEK	Mitogen-Activated Protein Kinase Kinase
MSI-H	Microsatellite Instability-High
MSS	Microsatellite Stable
NCI-MATCH	National Cancer Institute Molecular Analysis for Therapy Choice
NGS	Next-Generation Sequencing
NRG1	Neuregulin 1
NSCLC	Non-Small-Cell Lung Cancer
NTRK	Neurotrophic Tropomyosin Receptor Kinase
ORR	Objective Response Rate
OS	Overall Survival
PARP	Poly (ADP-Ribose) Polymerase
PD-1	Programmed Cell Death Protein 1
PD-L1	Programmed Death-Ligand 1
PFS	Progression-Free Survival
POLE	DNA Polymerase Epsilon
POLD1	DNA Polymerase Delta 1
RET	Rearranged During Transfection
RNA	Ribonucleic Acid
ROS1	c-ros Oncogene 1 (Receptor Tyrosine Kinase)
SCC	Squamous Cell Carcinoma
SCLC	Small-Cell Lung Cancer
T-DXd	Fam-Trastuzumab Deruxtecan
TKI	Tyrosine Kinase Inhibitor
TMB	Tumor Mutational Burden
TMB-H	Tumor Mutational Burden-High
TRK	Tropomyosin Receptor Kinase
WHO	World Health Organization